May 8, 2020
Daiichi Sankyo said on May 7 that it has filed an application seeking an additional indication for Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody drug conjugate (ADC), for the treatment of HER2 positive metastatic gastric cancer. The submission, the world’s first...read more